세계의 뇌종양 진단 및 치료 시장 - 규모, 점유율, 동향 분석 보고서 : 유형별, 제품별, 진단별, 치료별, 최종 용도별, 지역별 부문 예측(2025-2030년)

Brain Tumor Diagnosis And Therapeutics Market Size, Share & Trends Analysis Report By Type (Primary, Secondary), By Product, By Diagnosis (MRI, CT, PET-CT), By Therapeutics, By End Use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 뇌종양 진단 및 치료 시장 성장과 동향

세계의 뇌종양 진단 및 치료 시장 규모는 2030년 49억 4,000만 달러에 달할 것으로 예측되며, 2025-2030년까지 CAGR 7.3%를 나타낼 것으로 예측됩니다.

이 시장은 노인 증가와 함께 다양한 뇌종양, 특히 교아종의 이환율이 증가하고 있기 때문에 예측 기간 동안 유리한 성장을 이룰 것으로 예상됩니다.

의료 부문에서 공공 민간 파트너십(PPP) 증가는 영상 진단 및 방사선학 서비스의 현대화를 추진하고 있으며, 이 산업의 확대를 뒷받침하고 있습니다. Sodium Magnetic Resonance Imaging(23Na MRI), Positron Emission Tomography(PET), Chemical Exchange Saturation Transfer(CEST)와 같은 신기술은 다기관 공동 임상시험 환경에서 뇌종양의 반응을 검출하는 데 사용됩니다. 또한, 이러한 기술은 치료에 대한 종양의 반응을 정량적으로 영상화하는데 유용하며, 이로써 치료 중 사용을 촉진합니다.

이러한 기술은 생리학 및 세포 대사에 대한 정보를 제공함으로써 해부학 이미징에 그치지 않고 MRI를 확대하고 진단 효율을 높일 수있는 가능성을 가지고 있습니다. 따라서 이 시장은 예측 기간 동안 생산적인 성장을 이룰 것으로 예상됩니다.

게다가 악성 종양의 세포 수준에서 세포 생물학을 이해하고 악성 종양과 관련된 유전자 변이를 확인하기 위한 분자진단 연구가 진행 중이며 산업 성장에 크게 기여할 것으로 예상됩니다.

한편 뇌종양 진단에 드는 비용은 450-1만 2,200달러로 고액이기 때문에 세계 뇌종양 진단 시장의 성장을 방해할 가능성이 높습니다.

뇌종양 진단 및 치료 시장 보고서 하이라이트

• 영상 기술의 발전으로 시장 내 기능이 크게 향상되었습니다.
• 1차 부문이 시장을 독점해 2024년에는 62.7%의 점유율을 차지했습니다.
• 스테인 및 바니스가 시장을 선도해 2024년 점유율은 25.7%였습니다.
• CT 스캔은 2024년에 25.8%의 판매 점유율을 차지해 시장을 독점했습니다.
• 수술은 2024년에 35.6%의 최대 점유율을 차지했습니다.
• 종양 치료 센터는 2024년 48.5%의 최대 시장 점유율을 차지했습니다.
• 북미의 뇌종양 진단 및 치료 시장은 2024년 41.9%의 수익 점유율로 세계 시장을 독점했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 뇌종양 진단 및 치료 시장의 변수, 동향, 범위

• 시장 계통의 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 산업 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 뇌종양 진단 및 치료 시장 : 유형 비즈니스 분석

• 유형 시장 점유율, 2024년과 2030년
• 유형 부문 대시보드
• 시장 규모와 예측과 동향 분석, 유형별, 2018-2030년
• 1차
• 2차

제5장 뇌종양 진단 및 치료 시장 : 제품 비즈니스 분석

• 제품 시장 점유율, 2024년과 2030년
• 제품 부문 대시보드
• 시장 규모와 예측과 동향 분석, 제품별, 2018-2030년
• 스테인 및 바니시
• 셀락
• 래커
• 기타

제6장 뇌종양 진단 및 치료 시장 : 진단 비즈니스 분석

• 진단 시장 점유율, 2024년과 2030년
• 진단 부문 대시보드
• 시장 규모와 예측과 동향 분석, 진단별, 2018-2030년
• MRI
• CT 스캔
• 조직 샘플 채취
• PET-CT 스캔
• 뇌동맥 조영
• 요추천자
• 분자 검사
• 뇌전도
• 기타

제7장 뇌종양 진단 및 치료 시장 : 치료 비즈니스 분석

• 치료 시장 점유율, 2024년과 2030년
• 치료 부문 대시보드
• 시장 규모와 예측과 동향 분석, 치료별, 2018-2030년
• 수술
• 방사선치료
• 화학요법
• 면역요법
• 표적요법
• 기타

제8장 뇌종양 진단 및 치료 시장 : 최종 용도 비즈니스 분석

• 최종 용도 시장 점유율, 2024년과 2030년
• 최종 용도 부문 대시보드
• 시장 규모와 예측과 동향 분석, 최종 용도별, 2018-2030년
• 병원
• 종양치료센터
• 기타

제9장 뇌종양 진단 및 치료 시장 :지역별, 추정 및 동향 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 국가별, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별, 2018-2030년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 덴마크
  • 스웨덴
• 아시아태평양
  • 국가별, 2018-2030년
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 국가별, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별, 2018-2030년
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제10장 경쟁 구도

• 참가자 개요
• 기업의 시장 포지셔닝 분석
• 기업 분류
• 전략 매핑
• 기업 프로파일/상장 기업
  • Amgen Inc.
  • AstraZeneca
  • Bayer Corporation
  • GE HealthCare
  • F. Hoffmann-La Roche Ltd
  • Eisai Co., Ltd.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Shimadzu Corporation
  • Siemens Healthineers AG

JHS

영문 목차

영문목차

Brain Tumor Diagnosis And Therapeutics Market Growth & Trends:

The global brain tumor diagnosis and therapeutics market size is expected to reach USD 4.94 billion in 2030 and is projected to grow at a CAGR of 7.3% from 2025 to 2030. The market is expected to pose lucrative growth over the forecast period, owing to the increasing incidence of various brain cancers, particularly glioblastoma, coupled with the rising geriatric population.

Increasing Public-Private Partnerships (PPPs) in the health sector, which are modernizing diagnostic imaging and radiology services, are supporting the expansion of this industry. Emerging technologies like Sodium Magnetic Resonance Imaging(23Na MRI), Positron Emission Tomography (PET), and Chemical Exchange Saturation Transfer (CEST) are used to detect the response of brain tumors in multicenter clinical trial settings. In addition, these technologies are helpful in quantitatively imaging tumor response to therapies, thereby promoting their use during treatment.

These technologies have the potential to extend MRI beyond anatomical imaging by providing information on physiology and cellular metabolism, thereby increasing the efficiency of diagnosis. Hence, the market is expected to witness productive growth over the forecast period.

Moreover, ongoing research in molecular diagnostics to understand cell biology at the cellular level of malignancy and identification of gene mutations associated with malignancy is anticipated to significantly contribute toward the growth of the industry.

On the other hand, the high cost of diagnosing brain tumors, which ranges from USD 450 to 12,200, is likely to hinder the growth of the global brain tumor diagnosis market.

Brain Tumor Diagnosis And Therapeutics Market Report Highlights:

• Advancements in diagnostic imaging technologies have significantly enhanced the capabilities within the market
• The primary segment dominated the market and accounted for a share of 62.7% in 2024
• Stains & varnishes led the market and accounted for a share of 25.7% in 2024
• CT scan dominated the market with a revenue share of 25.8% in 2024
• Surgery held the largest market share of 35.6% in 2024
• Oncology treatment centers held the largest market share of 48.5% in 2024
• North America brain tumor diagnosis and therapeutics market dominated the global market with a revenue share of 41.9% in 2024

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Product
  • 1.2.3. Diagnosis
  • 1.2.4. Therapeutics
  • 1.2.5. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Brain Tumor Diagnosis and Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Brain Tumor Diagnosis and Therapeutics Market: Type Business Analysis

• 4.1. Type Market Share, 2024 & 2030
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Primary
  • 4.4.1. Primary Market, 2018 - 2030 (USD Million)
  • 4.4.2. Meningioma
    • 4.4.2.1. Meningioma Market, 2018 - 2030 (USD Million)
  • 4.4.3. Gliomas
    • 4.4.3.1. Gliomas Market, 2018 - 2030 (USD Million)
  • 4.4.4. Astrocytomas
    • 4.4.4.1. Astrocytomas Market, 2018 - 2030 (USD Million)
  • 4.4.5. Pituitary Tumors
    • 4.4.5.1. Pituitary Tumors Market, 2018 - 2030 (USD Million)
  • 4.4.6. Others
    • 4.4.6.1. Others Market, 2018 - 2030 (USD Million)
• 4.5. Secondary
  • 4.5.1. Secondary Market, 2018 - 2030 (USD Million)

Chapter 5. Brain Tumor Diagnosis and Therapeutics Market: Product Business Analysis

• 5.1. Product Market Share, 2024 & 2030
• 5.2. Product Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 5.4. Stains & Varnishes
  • 5.4.1. Stains & Varnishes Market, 2018 - 2030 (USD Million)
• 5.5. Shellacs
  • 5.5.1. Shellacs Market, 2018 - 2030 (USD Million)
• 5.6. Lacquers
  • 5.6.1. Lacquers Market, 2018 - 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Brain Tumor Diagnosis and Therapeutics Market: Diagnosis Business Analysis

• 6.1. Diagnosis Market Share, 2024 & 2030
• 6.2. Diagnosis Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Diagnosis, 2018 to 2030 (USD Million)
• 6.4. MRI
  • 6.4.1. MRI Market, 2018 - 2030 (USD Million)
• 6.5. CT Scan
  • 6.5.1. CT Scan Market, 2018 - 2030 (USD Million)
• 6.6. Tissue Sampling
  • 6.6.1. Tissue Sampling Market, 2018 - 2030 (USD Million)
• 6.7. PET-CT scan
  • 6.7.1. PET-CT scan Market, 2018 - 2030 (USD Million)
• 6.8. Cerebral Arteriogram
  • 6.8.1. Cerebral Arteriogram Market, 2018 - 2030 (USD Million)
• 6.9. Lumbar Puncture
  • 6.9.1. Lumbar Puncture Market, 2018 - 2030 (USD Million)
• 6.10. Molecular Testing
  • 6.10.1. Molecular Testing Market, 2018 - 2030 (USD Million)
• 6.11. EEG
  • 6.11.1. EEG Market, 2018 - 2030 (USD Million)
• 6.12. Others
  • 6.12.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Brain Tumor Diagnosis and Therapeutics Market: Therapeutics Business Analysis

• 7.1. Therapeutics Market Share, 2024 & 2030
• 7.2. Therapeutics Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Therapeutics, 2018 to 2030 (USD Million)
• 7.4. Surgery
  • 7.4.1. Surgery Market, 2018 - 2030 (USD Million)
• 7.5. Radiation Therapy
  • 7.5.1. Radiation Therapy Market, 2018 - 2030 (USD Million)
• 7.6. Chemotherapy
  • 7.6.1. Chemotherapy Market, 2018 - 2030 (USD Million)
• 7.7. Immunotherapy
  • 7.7.1. Immunotherapy Market, 2018 - 2030 (USD Million)
• 7.8. Targeted Therapy
  • 7.8.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
• 7.9. Others
  • 7.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Brain Tumor Diagnosis and Therapeutics Market: End Use Business Analysis

• 8.1. End Use Market Share, 2024 & 2030
• 8.2. End Use Segment Dashboard
• 8.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 8.4. Hospitals
  • 8.4.1. Hospitals Market, 2018 - 2030 (USD Million)
• 8.5. Oncology Treatment Centers
  • 8.5.1. Oncology Treatment Centers Market, 2018 - 2030 (USD Million)
• 8.6. Others
  • 8.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 9. Brain Tumor Diagnosis and Therapeutics Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.4. North America
  • 9.4.1. North America Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 9.4.2. U.S.
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Regulatory Framework
    • 9.4.2.3. Competitive Insights
    • 9.4.2.4. U.S. Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.4.3. Canada
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Regulatory Framework
    • 9.4.3.3. Competitive Insights
    • 9.4.3.4. Canada Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.4.4. Mexico
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Regulatory Framework
    • 9.4.4.3. Competitive Insights
    • 9.4.4.4. Mexico Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 9.5. Europe
  • 9.5.1. Europe Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 9.5.2. UK
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Regulatory Framework
    • 9.5.2.3. Competitive Insights
    • 9.5.2.4. UK Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.5.3. Germany
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Regulatory Framework
    • 9.5.3.3. Competitive Insights
    • 9.5.3.4. Germany Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.5.4. France
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Regulatory Framework
    • 9.5.4.3. Competitive Insights
    • 9.5.4.4. France Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.5.5. Italy
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Regulatory Framework
    • 9.5.5.3. Competitive Insights
    • 9.5.5.4. Italy Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.5.6. Spain
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Regulatory Framework
    • 9.5.6.3. Competitive Insights
    • 9.5.6.4. Spain Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.5.7. Norway
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Regulatory Framework
    • 9.5.7.3. Competitive Insights
    • 9.5.7.4. Norway Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.5.8. Denmark
    • 9.5.8.1. Key Country Dynamics
    • 9.5.8.2. Regulatory Framework
    • 9.5.8.3. Competitive Insights
    • 9.5.8.4. Denmark Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.5.9. Sweden
    • 9.5.9.1. Key Country Dynamics
    • 9.5.9.2. Regulatory Framework
    • 9.5.9.3. Competitive Insights
    • 9.5.9.4. Sweden Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 9.6.2. Japan
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Regulatory Framework
    • 9.6.2.3. Competitive Insights
    • 9.6.2.4. Japan Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.6.3. China
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Regulatory Framework
    • 9.6.3.3. Competitive Insights
    • 9.6.3.4. China Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.6.4. India
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Regulatory Framework
    • 9.6.4.3. Competitive Insights
    • 9.6.4.4. India Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.6.5. South Korea
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Regulatory Framework
    • 9.6.5.3. Competitive Insights
    • 9.6.5.4. South Korea Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.6.6. Australia
    • 9.6.6.1. Key Country Dynamics
    • 9.6.6.2. Regulatory Framework
    • 9.6.6.3. Competitive Insights
    • 9.6.6.4. Australia Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.6.7. Thailand
    • 9.6.7.1. Key Country Dynamics
    • 9.6.7.2. Regulatory Framework
    • 9.6.7.3. Competitive Insights
    • 9.6.7.4. Thailand Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 9.7. Latin America
  • 9.7.1. Latin America Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 9.7.2. Brazil
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Regulatory Framework
    • 9.7.2.3. Competitive Insights
    • 9.7.2.4. Brazil Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.7.3. Argentina
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Regulatory Framework
    • 9.7.3.3. Competitive Insights
    • 9.7.3.4. Argentina Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 9.8. MEA
  • 9.8.1. MEA Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 9.8.2. South Africa
    • 9.8.2.1. Key Country Dynamics
    • 9.8.2.2. Regulatory Framework
    • 9.8.2.3. Competitive Insights
    • 9.8.2.4. South Africa Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key Country Dynamics
    • 9.8.3.2. Regulatory Framework
    • 9.8.3.3. Competitive Insights
    • 9.8.3.4. Saudi Arabia Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.8.4. UAE
    • 9.8.4.1. Key Country Dynamics
    • 9.8.4.2. Regulatory Framework
    • 9.8.4.3. Competitive Insights
    • 9.8.4.4. UAE Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key Country Dynamics
    • 9.8.5.2. Regulatory Framework
    • 9.8.5.3. Competitive Insights
    • 9.8.5.4. Kuwait Brain Tumor Diagnosis and Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Participant Overview
• 10.2. Company Market Position Analysis
• 10.3. Company Categorization
• 10.4. Strategy Mapping
• 10.5. Company Profiles/Listing
  • 10.5.1. Amgen Inc.
    • 10.5.1.1. Overview
    • 10.5.1.2. Financial Performance
    • 10.5.1.3. Product Benchmarking
    • 10.5.1.4. Strategic Initiatives
  • 10.5.2. AstraZeneca
    • 10.5.2.1. Overview
    • 10.5.2.2. Financial Performance
    • 10.5.2.3. Product Benchmarking
    • 10.5.2.4. Strategic Initiatives
  • 10.5.3. Bayer Corporation
    • 10.5.3.1. Overview
    • 10.5.3.2. Financial Performance
    • 10.5.3.3. Product Benchmarking
    • 10.5.3.4. Strategic Initiatives
  • 10.5.4. GE HealthCare
    • 10.5.4.1. Overview
    • 10.5.4.2. Financial Performance
    • 10.5.4.3. Product Benchmarking
    • 10.5.4.4. Strategic Initiatives
  • 10.5.5. F. Hoffmann-La Roche Ltd
    • 10.5.5.1. Overview
    • 10.5.5.2. Financial Performance
    • 10.5.5.3. Product Benchmarking
    • 10.5.5.4. Strategic Initiatives
  • 10.5.6. Eisai Co., Ltd.
    • 10.5.6.1. Overview
    • 10.5.6.2. Financial Performance
    • 10.5.6.3. Product Benchmarking
    • 10.5.6.4. Strategic Initiatives
  • 10.5.7. Bristol-Myers Squibb Company
    • 10.5.7.1. Overview
    • 10.5.7.2. Financial Performance
    • 10.5.7.3. Product Benchmarking
    • 10.5.7.4. Strategic Initiatives
  • 10.5.8. Pfizer Inc.
    • 10.5.8.1. Overview
    • 10.5.8.2. Financial Performance
    • 10.5.8.3. Product Benchmarking
    • 10.5.8.4. Strategic Initiatives
  • 10.5.9. Shimadzu Corporation
    • 10.5.9.1. Overview
    • 10.5.9.2. Financial Performance
    • 10.5.9.3. Product Benchmarking
    • 10.5.9.4. Strategic Initiatives
  • 10.5.10. Siemens Healthineers AG
    • 10.5.10.1. Overview
    • 10.5.10.2. Financial Performance
    • 10.5.10.3. Product Benchmarking
    • 10.5.10.4. Strategic Initiatives

관련자료